Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
Osteoporosis: A Perspective for 2024
May 16, 2024
Virtual via Zoom

Activity Coordinator:
Erin South (Erin.South@fda.hhs.gov)
Description

Strong bones are essential to health and quality of life. Osteoporosis and fragility fractures are common and can be debilitating but there are steps we can take to help reduce the risk. Because osteoporosis is asymptomatic until the first clinical fracture, many women do not realize they are at risk. This lecture will summarize the current approach to assessing bone health, as well as preventing and treating osteoporosis with a focus on postmenopausal women.

References
  • Walker et al. Postmenopausal Osteoporosis. NEJM 2023; 389: 1979-1991 https://www.nejm.org/doi/full/10.1056/NEJMcp2307353
  • LeBoff et al. Clinician’s guide to prevention and treatment of osteoporosis. OI 2022; 33(10):2049-2102 https://pubmed.ncbi.nlm.nih.gov/35478046/
  • Eastell et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. JCEM 2019; May 1;104(5):1595-1622 https://pubmed.ncbi.nlm.nih.gov/30907953/
  • Camacho et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY; Endocrine Practice 2020; 2020 May;26(5):564-570 https://pubmed.ncbi.nlm.nih.gov/32427525/
  • Ensrud et al. Osteoporosis 2024. Annals of Internal Medicine Jan;177(1):ITC1-ITC16. doi: 10.7326/AITC202401160 https://pubmed.ncbi.nlm.nih.gov/38190715/
Learning Objectives
  • Identify the causes and consequences of osteoporosis and quantify the burden of disease.
  • Discuss strategies used to assess fracture risk and to diagnose osteoporosis.
  • Describe the options for the prevention and treatment of osteoporosis.
  • Define and explain the osteoporosis care gap.
Target Audience
This activity is intended for physicians, pharmacists, nurses, and all other interested stakeholders.
Registration Information
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.
Agenda
Day 1 May 16, 2024
Time Topic Speaker
12:00 - 1:00 PM EDT Osteoporosis: A Perspective for 2024 Marcella Walker, MD
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-24-063-L01-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit

All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.

Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor. If you do not see your credit reflected on CPE Monitor* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov. *CPE Monitor sets a strict 60-day limit on uploading credits.

Disclosure

Faculty
  • Walker, Marcella, MD, Professor of Medicine, Columbia University - I have the following relationship(s): Alexion - Advisory Board; Amgen - research grant

Planning Committee
  • Bersoff-Matcha, Susan, MD, Deputy Director, OC - nothing to disclose
  • Shahidzadeh, Rokhsareh, RN, MSN, Senior Regulatory Health Education Specialist, FDA - nothing to disclose
  • South, Erin, PharmD, Pharmacist, FDA - nothing to disclose

CE Consultation and Accreditation Team
  • Bueide, Rachel E., MPhil, Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.
Requirements for Certificate of Completion (Non CE)
Must attend 100% of the activity.